N/A
N=214
Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
Colo-rectal Cancer · Polyp of Colon · Adenomatous Polyp of Colon
Bottom Line
View on ClinicalTrials.gov: NCT04551014 ↗Enrolled (actual)
214
Serious AEs
1.4%
Results posted
Sep 2022
Primary outcome: Primary: Number of Polyps With Complete Resection — 140; 145 Polyps — p=0.424
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Use of EverLift (Device); Without use of EverLift (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Polyps With Complete Resection |
140; 145 | 0.424 |
| SECONDARY Time to Resection |
109.8; 38.8 | <0.0001 sig |
| SECONDARY Number of Polyps Requiring Multiple Snare Attempts to Achieve Complete Endoscopic Polypectomy. |
6; 5 | 0.697 |
| SECONDARY Number of Patients With Procedural Complications |
1; 2 | — |
Summary
The focus of the study is to evaluate impact of submucosal injection of EverLift in achieving complete resection during polypectomy of polyps 4-9mm during colonoscopy.
Eligibility Criteria
Inclusion Criteria
- Patients 18 years or older
- Polyps 4-9mm
Exclusion Criteria
- Pregnant
- Inflammatory bowel disease
- Polyposis syndromes
Data sourced from ClinicalTrials.gov (NCT04551014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.